Stocks Health care DGX
NYSE · Health careQuest Diagnostics Inc (DGX)
Quest Diagnostics Inc brought in $11.6B of revenue over the twelve months to June 30, 2026, up 9.9% from a year earlier. Net income was $1.1B, a net margin of 9.2%. Operating cash flow minus capital spending left $1.4B of free cash flow in fiscal 2025. At June 30, 2026 it held $626M in cash against $5.6B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 23, 2026.
Key facts about Quest Diagnostics Inc
- Net worth
- Quest Diagnostics Inc has a market value (market cap) of $25.6B at the latest share price, and shareholders' equity of $7.5B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $11B (+11.8% year on year), with net income of $992M. Over the 12 months to June 30, 2026: revenue $11.6B, net income $1.1B.
- Cash flow
- In fiscal 2025 operations brought in $1.9B of cash; after $527M of capital spending, free cash flow was $1.4B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 23, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Quest Diagnostics Inc's next report is expected around October 20, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Quest Diagnostics Inc does
Quest Diagnostics Inc is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NYSE under the ticker DGX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $11B | $992M | $8.75 | $1.4B |
| 2024 | $9.9B | $871M | $7.69 | $909M |
| 2023 | $9.3B | $854M | $7.49 | $864M |
| 2022 | $9.9B | $946M | $7.97 | $1.3B |
| 2021 | $10.8B | $2B | $15.55 | $1.8B |
| 2020 | $9.4B | $1.4B | $10.47 | $1.6B |
Full financial statements: income, balance sheet and cash flow
Where DGX ranks in Health care
Dividends
It paid out $353M in cash dividends, 36% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | n/a | $353M | 36% |
| 2024 | n/a | $331M | 38% |
| 2023 | n/a | $314M | 37% |
| 2022 | n/a | $305M | 32% |
| 2021 | n/a | $309M | 15% |
| 2020 | n/a | $297M | 21% |
Latest SEC filings
What Quest Diagnostics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- July 23, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 10% to $3B versus the same quarter last year; diluted EPS $2.84 versus $2.47.
- July 23, 2026
- June 18, 2026
- May 21, 2026
- May 8, 2026
- May 1, 2026Other event 8-K
- April 30, 2026Passive stake (5% or more) SCHEDULE 13G
- April 29, 2026Passive stake (5% or more) SCHEDULE 13G
- April 28, 2026
What is DGX worth? A DCF from its reported cash flow
Insider trades
What the people running Quest Diagnostics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $8.3M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 1, 2026 | Davis J. E.CEO and President, Director | Soldpre-planned (10b5-1) | 10,000 | $2.4M |
| August 28, 2026 | Prevoznik Michael ESVP & General Counsel | Exercised options | 22,677 | $2.5M |
| August 28, 2026 | Prevoznik Michael ESVP & General Counsel | Soldpre-planned (10b5-1) | 16,010 | $3.9M |
| August 28, 2026 | Prevoznik Michael ESVP & General Counsel | Soldpre-planned (10b5-1) | 6,237 | $1.5M |
| August 28, 2026 | Prevoznik Michael ESVP & General Counsel | Soldpre-planned (10b5-1) | 430 | $105.1K |
| August 28, 2026 | Prevoznik Michael ESVP & General Counsel | Gave as a gift | 1,000 | - |
| July 28, 2026 | Delaney Mark ESVP & Chief Commercial Officer | Soldpre-planned (10b5-1) | 1,600 | $376.3K |
| July 22, 2026 | Delaney Mark ESVP & Chief Commercial Officer | Other change | 34 | $7K |
Who owns DGX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.53% | April 30, 2026 |
| Vanguard Portfolio Management13G, passive | 5.54% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 1,105 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 9,275,411 | +103,119 |
| Vanguard Capital Management LLC | 7,233,394 | +87,722 |
| Vanguard Portfolio Management LLC | 6,131,045 | +49,645 |
| State Street Corp | 5,516,643 | +135,822 |
| Boston Partners | 4,744,473 | +732,241 |
| Jpmorgan Chase & Co | 3,520,438 | -326,018 |
| Geode Capital Management, LLC | 3,137,873 | +51,565 |
| Morgan Stanley | 2,460,497 | -19,223 |
| EdgePoint Investment Group Inc. | 2,247,568 | +3,699 |
| Dimensional Fund Advisors LP | 1,988,048 | +38,513 |
| Bank of America Corp | 1,935,133 | +182,231 |
| Grantham, Mayo, Van Otterloo & Co. LLC | 1,888,207 | +5,183 |
| Wells Fargo & Company | 1,751,220 | -11,549 |
| Davis Selected Advisers | 1,555,612 | -62,201 |
| Victory Capital Management Inc | 1,550,556 | -295,780 |
| Norges Bank | 1,406,620 | new |
| Fmr LLC | 1,398,735 | +456,517 |
| Invesco Ltd. | 1,379,115 | -259,372 |
| Northern Trust Corp | 1,127,454 | +13,235 |
| Goldman Sachs Group Inc | 982,694 | -366,000 |
Insiders
18 insiders reported holding 477,370 shares in total, about $110.9M at the last price.
| Holder | Shares |
|---|---|
| Davis J. E.CEO and President, Director | 122,423 |
| Doherty Catherine T.EVP, Regional Businesses | 67,122 |
| Prevoznik Michael ESVP & General Counsel | 36,557 |
| Deppe Michael JSVP, Corp. Controller & CAO | 35,196 |
| Samad SamExecutive Vice President & CFO | 33,478 |
| Ring Timothy MDirector | 31,140 |
| Pfeiffer Gary MDirector | 31,005 |
| Main Timothy LDirector | 22,460 |
| Gregg Vicky BDirector | 18,386 |
| Plewman PatrickSVP for Diagnostic Services | 15,293 |
Questions about DGX
What does Quest Diagnostics Inc do?
Quest Diagnostics Inc is a company in the Health care sector, listed on NYSE as DGX. Its shares trade on NYSE under the ticker DGX.
What is Quest Diagnostics Inc's net worth?
Quest Diagnostics Inc has a market value (market cap) of $25.6B at the latest share price, and shareholders' equity of $7.5B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Quest Diagnostics Inc profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $1.1B on revenue of $11.6B, a net margin of 9.2%.
How much revenue does Quest Diagnostics Inc make?
Over the twelve months to June 30, 2026 Quest Diagnostics Inc reported revenue of $11.6B. That is 9.9% more than a year earlier.
When did Quest Diagnostics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 23, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 2, 2026.
When is Quest Diagnostics Inc's next earnings report?
Quest Diagnostics Inc's next report is expected around October 20, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare DGX with
Follow DGX
Get an email when Quest Diagnostics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow DGX: get an email when it filesWhere the numbers come from
Financial figures are the values Quest Diagnostics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.